BIOMOTION SCIENCES WARRANT
NASDAQ: SLXNW (Biomotion Sciences Warrant)
Kemas kini terakhir: 2 jam lalu0.030
-0.02 (-35.48%)
| Penutupan Terdahulu | 0.047 |
| Buka | 0.032 |
| Jumlah Dagangan | 47,008 |
| Julat 52 Minggu |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1,405.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.94% |
| Nisbah Semasa (MRQ) | 0.640 |
| Aliran Tunai Operasi (OCF TTM) | -8.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.41 M |
| Pulangan Atas Aset (ROA TTM) | -193.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -116.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Biomotion Sciences Warrant | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | 1.00 |
|
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Security Benefit Life Insurance Co /Ks/ | 30 Jun 2026 | 150,000 |
| Kepos Capital Lp | 31 Mar 2026 | 100,000 |
| Gabelli & Co Investment Advisers, Inc. | 31 Mar 2026 | 38,150 |
| Dupont Capital Management Corp | 31 Mar 2026 | 32,500 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |